Overview

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
Phase:
PHASE2
Details
Lead Sponsor:
Philogen S.p.A.
Treatments:
Lomustine